Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
DexCom Inc Market Cap
From what 13 stock analysts predict, the share price for DexCom Inc (DXCM) might increase by 26.23% in the next year. This is based on a 12-month average estimation for DXCM. Price targets go from $122.00 to $161.00. The majority of stock analysts believe DXCM is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
DexCom Inc has a total of 13 Wall St Analyst ratings. There are 11 buy ratings, 2 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that DexCom Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| matt miksic Barclays | Hold | $138.0 | rated | Feb 9, 2024 |
| patrick wood Morgan Stanley | Hold | $122.0 | maintained | Dec 4, 2023 |
| cecilia furlong Morgan Stanley | Hold | $131.0 | initiatedcoverage | May 30, 2023 |
| ravi misra Berenberg Bank | Hold | None | rated | Dec 13, 2021 |
| suraj kalia Oppenheimer | Hold | $125.0 | rated | Aug 1, 2019 |
| isaac ro Goldman Sachs | Hold | $125.0 | upgraded | Oct 19, 2018 |
| issac ro Goldman Sachs | Hold | $125.0 | upgraded | Oct 19, 2018 |
| lawrence keusch Raymond James | Hold | None | reiterated | Mar 6, 2018 |
| amit hazan Goldman Sachs | Hold | $47.0 | rated | Dec 10, 2014 |
| greg simpson Wunderlich | Hold | $20.0 | downgraded | Jun 10, 2013 |
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
When did it IPO
2005
Staff Count
9,500
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Kevin Ronald Sayer
Market Cap
$45.44B
In 2023, DXCM generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that DXCM's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
IDXX-USD
$551.21
$423.45
PAYX-USD
$123.38
MCHP-USD
$81.61
$103.34
$82
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
